BUY Aurobindo Pharma — Arun Kumar Mantri, 17 Sept 2026

byArun Kumar MantriHorizon: BTST17 Sept 2026, 3:14 pm ISTvia CNBC Awaaz.

Entry₹1,684.1Inferred

Target₹1,705

Stop loss₹1,670-0.84% risk

CMP₹1,6904h ago

Active+0.35%+0.89%upside left 18h left

Follow Arun Kumar Mantri for new calls(16% target hit, 76 closed calls)Get alerts Watch AUROPHARMA for new buy/sell callsGet alerts See 4 other BTST picks this session

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 17 Sept, 8:31 pm IST

9 supporting0 opposing

Supports the BUY call (9)

1 advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · adjacent horizon·17 Sept · today

JM Financial sees up to 28% upside in Dr Reddy’s and Aurobindo Pharma. Should you buy?

NewsEt-Markets·16 Sept · yesterday

Aurobindo Pharma Gets First USFDA Nod For First Metered-Dose Inhaler

NewsNdtv-Profit·15 Sept · 2d ago

Aurobindo Pharma gets US FDA nod to sell first metered-dose asthma inhaler in US

NewsCnbc-Tv18·15 Sept · 2d ago

Aurobindo Pharma received final US FDA approval for its Beclomethasone Dipropionate HFA Inhalation Aerosol in 40 mcg and 80 mcg strengths.

BSE · Company Update·15 Sept · 2d ago

Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.